Key result
TPP+-LNO2 protects cardiomyocytes from ischaemia-reperfusion injury better than LNO2 by modifying mitochondrial proteins.
Why the study?
Does TPP+-LNO2 protect murine cardiomyocytes from simulated ischaemia-reperfusion injury better than LNO2?
Does TPP+-LNO2 protect murine cardiomyocytes from simulated ischaemia-reperfusion injury better than LNO2?
Answers are grounded in this paper and cite their sources.
Mitochondrially targeted nitro-linoleate (TPP+-LNO2) offers enhanced cardioprotection against ischaemia-reperfusion injury in preclinical models by targeting mitochondrial ANT1.
BACKGROUND AND PURPOSE: Cardiac ischaemia-reperfusion (IR) injury remains a significant clinical problem with limited treatment options available. We previously showed that cardioprotection against IR injury by nitro-fatty acids, such as nitro-linoleate (LNO2 ), involves covalent modification of mitochondrial adenine nucleotide translocase 1 (ANT1). Thus, it was hypothesized that conjugation of LNO2 to the mitochondriotropic triphenylphosphonium (TPP(+) ) moiety would enhance its protective properties. EXPERIMENTAL APPROACH: TPP(+) -LNO2 was synthesized from aminopropyl-TPP(+) and LNO2 , and characterized by direct infusion MS/MS. Its effects were assayed in primary cultures of cardiomyocytes from adult C57BL/6 mice and in mitochondria from these cells, exposed to simulated IR (SIR) conditions (oxygen and metabolite deprivation for 1h followed by normal conditions for 1h) by measuring viability by LDH release and exclusion of Trypan blue. Nitro-alkylated mitochondrial proteins were also measured by Western blots, using antibodies to TPP(+) . KEY RESULTS: TPP(+) -LNO2 protected cardiomyocytes from SIR injury more potently than the parent compound LNO2 . In addition, TPP(+) -LNO2 modified mitochondrial proteins, including ANT1, in a manner sensitive to the mitochondrial uncoupler carbonylcyanide-p-trifluoromethoxyphenylhydrazone (FCCP) and the ANT1 inhibitor carboxyatractyloside. Similar protein nitro-alkylation was obtained in cells and in isolated mitochondria, indicating the cell membrane was not a significant barrier to TPP(+) -LNO2 . CONCLUSIONS AND IMPLICATIONS: Together, these results emphasize the importance of ANT1 as a target for the protective effects of LNO2 , and suggest that TPP(+) -conjugated electrophilic lipid compounds may yield novel tools for the investigation of cardioprotection.
No takes yet. Share an insight, caveat, or question.
Nadtochiy et al. (2013) studied Cardiac ischaemia-reperfusion (IR) injury. TPP(+)-LNO2 (mitochondrially targeted nitro-linoleate) vs. LNO2 (parent compound) was evaluated on Viability by LDH release and exclusion of Trypan blue. TPP(+)-LNO2 protected cardiomyocytes from simulated ischaemia-reperfusion injury more potently than the parent compound LNO2 and modified mitochondrial proteins including ANT1.
Synapse has enriched 10 related papers. Consider them for comparative context: